Conditions

Genetic conditions amenable to ASO therapy.

Antisense oligonucleotides can target a wide range of genetic mutations. Below are 20 conditions with active ASO research or approved drugs — each page explains the disease, the ASO mechanism, and what Pequliar provides.

DMDExon skipping

Duchenne Muscular Dystrophy

Personalized ASO design for Duchenne muscular dystrophy (DMD). Exon-skipping antisense oligonucleotides restore partial dystrophin production.

Learn more →
SMN1 / SMN2Splice switching (exon inclusion)

Spinal Muscular Atrophy

Personalized ASO design for spinal muscular atrophy (SMA). Splice-switching ASOs promote SMN2 exon 7 inclusion to restore SMN protein.

Learn more →
SCN1AUpregulation (targeted augmentation of nuclear gene output)

Dravet Syndrome

Personalized ASO design for Dravet syndrome (SCN1A). ASOs upregulate the functional SCN1A allele to restore sodium channel protein levels.

Learn more →
TTRGene silencing (RNase H-mediated degradation)

Hereditary Transthyretin Amyloidosis

Personalized ASO design for hereditary transthyretin amyloidosis (hATTR). Gene-silencing ASOs reduce toxic TTR protein production.

Learn more →
HTTGene silencing (RNase H-mediated degradation)

Huntington’s Disease

Personalized ASO design for Huntington’s disease (HTT). Gene-silencing ASOs reduce toxic mutant huntingtin protein production.

Learn more →
SOD1Gene silencing (RNase H-mediated degradation)

Amyotrophic Lateral Sclerosis (SOD1)

Personalized ASO design for SOD1-ALS. Gene-silencing ASOs reduce toxic SOD1 protein production. Tofersen (Qalsody) is FDA-approved.

Learn more →
UBE3AGene unsilencing (antisense transcript degradation)

Angelman Syndrome

Personalized ASO design for Angelman syndrome (UBE3A). ASOs degrade the UBE3A antisense transcript to reactivate the silenced paternal gene.

Learn more →
USH2AExon skipping

Usher Syndrome Type 2A

Personalized ASO design for Usher syndrome type 2A (USH2A). Exon-skipping ASOs restore a partially functional usherin protein.

Learn more →
CEP290Pseudoexon blocking

Leber Congenital Amaurosis Type 10

Personalized ASO design for Leber congenital amaurosis (CEP290). ASOs block a cryptic splice site to prevent pseudoexon inclusion.

Learn more →
DMPKGene silencing / RNA degradation (toxic RNA neutralization)

Myotonic Dystrophy Type 1

Personalized ASO design for myotonic dystrophy type 1 (DM1/DMPK). ASOs degrade toxic CUG-repeat RNA trapped in the nucleus.

Learn more →
MECP2Gene modulation (context-dependent)

Rett Syndrome

Personalized ASO design for Rett syndrome (MECP2). ASO strategies aim to restore MECP2 protein levels in neurons.

Learn more →
CLN3Splice switching / Exon skipping

Batten Disease (CLN3)

Personalized ASO design for Batten disease (CLN3). Milasen demonstrated that personalized ASOs can be designed for individual patients.

Learn more →
MT-TL1 (mitochondrial)Gene silencing (allele-selective, heteroplasmy shifting)

MELAS Syndrome

Personalized ASO design for MELAS syndrome (MT-TL1). ASOs selectively degrade mutant mitochondrial RNA to shift heteroplasmy.

Learn more →
FXNUpregulation (frataxin gene reactivation)

Friedreich Ataxia

Personalized ASO design for Friedreich ataxia (FXN). ASOs target the GAA repeat expansion to upregulate frataxin protein production.

Learn more →
PMP22Gene silencing (reduce PMP22 overexpression)

Charcot-Marie-Tooth Disease Type 1A

Personalized ASO design for Charcot-Marie-Tooth disease 1A (PMP22). Gene-silencing ASOs reduce PMP22 overexpression from the duplicated gene.

Learn more →
FBN1Allele-selective gene silencing or splice modulation (mutation-dependent)

Marfan Syndrome

Personalized ASO design for Marfan syndrome (FBN1). ASOs can target mutant FBN1 alleles to reduce dominant-negative fibrillin-1.

Learn more →
COL1A1Allele-selective gene silencing

Osteogenesis Imperfecta

Personalized ASO design for osteogenesis imperfecta (COL1A1). Allele-selective ASOs silence the mutant collagen allele.

Learn more →
COL5A1Allele-selective gene silencing or splice modulation (mutation-dependent)

Ehlers-Danlos Syndrome (Classical Type)

Personalized ASO design for classical Ehlers-Danlos syndrome (COL5A1). ASOs target mutant collagen V alleles to improve connective tissue.

Learn more →
SNRPN (15q11.2 imprinted region)Gene unsilencing (reactivation of paternally imprinted genes)

Prader-Willi Syndrome

Personalized ASO design for Prader-Willi syndrome (SNRPN/15q11). ASOs aim to reactivate silenced maternal copies of imprinted genes.

Learn more →
FMR1Gene reactivation (targeting CGG repeat-mediated silencing)

Fragile X Syndrome

Personalized ASO design for Fragile X syndrome (FMR1). ASOs aim to reactivate the epigenetically silenced FMR1 gene.

Learn more →

Don’t see your condition?

Pequliar can assess and design ASO candidates for nearly any genetic mutation. Describe your diagnosis and get started.

Start a design